Glaukos Corp. ( (GKOS) ) has released its Q4 earnings. Here is a breakdown of the information Glaukos Corp. presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases, notably known for pioneering Micro-Invasive Glaucoma Surgery (MIGS).
Glaukos Corporation reported strong financial results for the fourth quarter and full year of 2024, with record net sales driven by significant growth in its glaucoma segment. The company also introduced optimistic net sales guidance for 2025.
In the fourth quarter of 2024, Glaukos achieved a record net sales figure of $105.5 million, marking a 28% increase from the previous year. The glaucoma segment notably contributed $84.1 million, reflecting a 39% surge year-over-year. Despite a decrease in gross margin from 77% to 73%, the company improved its non-GAAP gross margin slightly to 82%. Operating expenses saw a modest increase, while operational losses narrowed compared to the prior year.
For the full year, net sales rose by 22% to $383.5 million, with a stable gross margin and a reduction in operational losses. The company ended the year with a robust cash position of approximately $324 million and no debt, setting a solid foundation for future growth.
Looking ahead, Glaukos has projected its 2025 net sales to be between $475 million and $485 million, indicating continued confidence in the company’s growth trajectory and strategic initiatives to advance its pipeline of novel therapies.
